P1/2, N=60, Recruiting, Ottawa Hospital Research Institute | Trial completion date: Oct 2022 --> Oct 2037 | Trial primary completion date: Oct 2022 --> Oct 2024
1 year ago
Trial completion date • Trial primary completion date
We report initial results from a single-arm, open-label study to determine the safety and efficacy of in-house manufactured CD19 CAR-T cells (entitled CLIC-1901) in participants with relapsed/refractory CD19 positive hematologic malignancies...Participants underwent lymphodepletion with fludarabine and cyclophosphamide, followed by infusion of non-cryopreserved CAR-T cells...Our experience may provide helpful guidance for other jurisdictions seeking to create feasible and sustainable CAR-T cell programs in research-oriented yet resource-constrained settings. https://clinicaltrials.gov/ct2/show/NCT03765177, identifier NCT03765177.